Research progress on immunotherapy resistance mechanisms of triple-negative breast cancer
10.11904/j.issn.1002-3070.2023.05.011
- VernacularTitle:三阴性乳腺癌免疫治疗耐药机制的研究进展
- Author:
Sitong CHU
1
;
Qingyong XU
Author Information
1. 哈尔滨医科大学附属肿瘤医院乳腺放疗科(哈尔滨 150081)
- Keywords:
Triple negative breast cancer;
Immunotherapy;
Immune resistance
- From:
Practical Oncology Journal
2023;37(5):449-453
- CountryChina
- Language:Chinese
-
Abstract:
Triple-negative breast cancer(TNBC)can benefit from immunotherapy because of its higher tumor mutational burden(TMB)and tumor-infiltrating lymphocytes.Although immunotherapy has made breakthroughs as an important treatment strategy for TNBC,recent clinical data suggest that a proportion of patients exhibit resistance to immunotherapy,or those who are ef-fective in treatment experience further recurrence or progression.The main reason for these poor prognosis is complex internal or ex-ternal immune escape mechanisms,which may be caused by abnormal antigen presentation,immunosuppressive tumor microenviron-ment,interactions with other immune checkpoints,and abnormal activation of tumor cell signaling.However,the research on the re-sistance mechanism of TNBC immunotherapy is still incomplete.This article will provide a review of the challenges faced by immuno-therapy and the potential mechanisms of TNBC develops resistance to immunotherapy.
